-
Patent Agency Ranking
公开(公告)号：US20190008966A1
公开(公告)日：2019-01-10
申请号：US16113027
申请日：2018-08-27
Applicant: AbbVie Inc.
Inventor： Chengbin Wu , Richard W. Dixon , Jonathan P. Belk , Hua Ying , Maria A. Argiriadi , Carolyn A. Cuff , Paul R. Hinton , Shankar Kumar , Terry L. Melim , Yan Chen
IPC: A61K45/06 , C07K14/47 , C07K16/24 , A61K39/395 , A61K38/00
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
-
公开(公告)号：US09592293B2
公开(公告)日：2017-03-14
申请号：US14101145
申请日：2013-12-09
Applicant: AbbVie Inc.
Inventor： Chengbin Wu , Richard W. Dixon , Jonathan P. Belk , Maria A. Argiriadi , Hua Ying , Carolyn A. Cuff , Terry L. Melim , Shankar Kumar , Paul R. Hinton , Yan Chen
IPC: A61K39/395 , A61K45/06 , C07K14/47 , C07K16/24 , A61K38/00
CPC classification number: A61K45/06 , A61K38/00 , A61K39/3955 , C07K14/47 , C07K16/244 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y02A50/385 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/463 , Y02A50/473 , Y02A50/478 , Y02A50/481
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
Abstract translation: 本发明包括IL-13结合蛋白。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-13具有高亲和力，并在体外和体内中和hIL-13活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-13和抑制hIL-13活性，例如在患有hIL-13活性有害的病症的人类受试者中。
-
公开(公告)号：US11344621B2
公开(公告)日：2022-05-31
申请号：US16113027
申请日：2018-08-27
Applicant: AbbVie Inc.
Inventor： Chengbin Wu , Richard W. Dixon , Jonathan P. Belk , Hua Ying , Maria A. Argiriadi , Carolyn A. Cuff , Paul R. Hinton , Shankar Kumar , Terry L. Melim , Yan Chen
IPC: A61K39/395 , A61K45/06 , C07K14/47 , C07K16/24 , A61K38/00
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
-
公开(公告)号：US10086076B2
公开(公告)日：2018-10-02
申请号：US15457264
申请日：2017-03-13
Applicant: AbbVie Inc.
Inventor： Chengbin Wu , Richard W. Dixon , Jonathan P. Belk , Hua Ying , Maria A. Argiriadi , Carolyn A. Cuff , Paul R. Hinton , Shankar Kumar , Terry L. Melim , Yan Chen
IPC: A61K39/395 , A61K45/06 , C07K14/47 , C07K16/24 , A61K38/00
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
-
公开(公告)号：US20150104452A1
公开(公告)日：2015-04-16
申请号：US14301305
申请日：2014-06-10
Applicant: AbbVie Inc.
Inventor： Tariq Ghayur , Edward B. Reilly , Andrew Phillips , Randy L. Bell , Yingchun Li , Hua Ying , Susan E. Morgan-Lappe , Gillian A. Kingsbury , Jieyi Wang , Suzanne M. Norvell , Junjian Liu
CPC classification number: C07K16/468 , A61K39/39533 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K16/28 , C07K16/2863 , C07K16/32 , C07K2317/31 , C07K2317/565 , C07K2317/64 , C07K2317/71 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2319/00 , G01N33/6872 , G01N33/74 , G01N2333/515 , G01N2333/705 , Y02A50/386 , Y02A50/41 , Y02A50/412 , Y02A50/58 , Y10S435/81
Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
-
-
-
-
Search Results
5
records
(took 0.048 seconds)
